ClinicalTrials.gg
RecruitingNCT06801223Updated Oct 6, 2026

A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection

A Phase 1 interventional study of Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours) and Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 8 hours) in Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC), sponsored by Innoviva Specialty Therapeutics. Recruiting at 4 sites in United States. Open to participants aged 1 Day to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Innoviva Specialty Therapeutics · Phase 1, Interventional, and Treatment

Updated Oct 6, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
1 Day to 18 Years
Sex
All
01

Study summary

The goal of this clinical trial is to investigate the use of Sulbactam-Durlobactam (SUL-DUR) in pediatric patients and is being conducted to collect pharmacokinetic (PK) and safety data to enable the identification of appropriate pediatric dosing regimens for patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections

02

Conditions studied

  • Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)

Keywords

  • Acinetobacter baumannii-calcoaceticus complex infection
  • Sulbactam-durlobactam
  • Hospital-acquired bacteria pneumonia
  • Ventilator-associated bacterial pneumonia
  • Acinetobacter
  • ABC infection
03

In context

Lead sponsor

Innoviva Specialty Therapeutics is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Day to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient from birth (defined as post-natal age of 7 days) to \<18 years of age at the time of written (and assent, if applicable) and is hospitalized.
  2. Patient and/or parent(s) or legal guardian(s) have provided the written informed consent and/or assent.
  3. Patient has confirmed or suspected diagnosis of ABC infection and requires IV antibiotics for treatment.
  4. Patient has expected survival of 30 days after enrollment in the study.
  5. If patient is an individual of or , then the patient must remain abstinent OR must utilize one of the highly effective methods of (ie, condom, combined oral contraceptive, implant, or injectable) from at least 30 days prior to screening until at least 30 days after administration of the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  1. Patient is a preterm infant, born at \<28 weeks gestational age.
  2. Patient has history of significant or allergic reaction to any β-lactam, any to the used in the formulation, or any contraindication to the use of β-lactam antibiotics. Note: For β-lactams, a history of a mild rash followed by uneventful re-exposure is not a contraindication to enrollment.
  3. Patient is in septic shock at the time of enrollment, defined as persistent hypotension despite adequate fluid resuscitation or vasopressive therapy.
  4. Patient is pregnant, breastfeeding, or intends to become pregnant.
  5. Patient is receiving peritoneal dialysis or cardiopulmonary bypass.
  6. Patient has received blood transfusion within 24 hours of study drug administration.
  7. Patient is a newborn with anemia who, in the opinion of the investigator, will not be able to tolerate the necessary blood draws to complete the study activities.
  8. Patient (or patient's mother, if the patient is being breastfed) is using or will need to use any medications known to inhibit organic anion transporter 1 (OAT1) (eg, probenecid).
  9. Patient has clinically significant renal, hepatic, or hemodynamic instability.
  10. For Cohorts 1 through 3 only: patient has weight outside of the 5th to 95th percentile based on age.
  11. Patient has an age-appropriate estimated that indicates renal impairment.
  12. Patient has the following laboratory results at Screening:

    1. (AST) or alanine aminotransferase (ALT) >3× (ULN) and,
    2. Total >2×ULN for age with conjugated/direct bilirubin >20% of the total. Note: Patients with AST or ALT up to 5×ULN are eligible if these elevations are acute and are documented as being directly related to the infectious process being treated.
  13. Patient has clinically significant abnormal laboratory test results not related to the underlying infection that might expose the patient to risk by participating in the trial, confound the results of the trial, or interfere with the patient's participation for the full duration of the trial.
  14. Patient (or patient's mother, if the patient is being breastfed) has participated in a clinical study involving medication or an investigational device within the last 30 days or 5 half-lives, whichever is longer, prior to first dose of the study drug.
  15. Patient has any condition that, in the opinion of the investigator, would compromise the safety of the patient or the quality of the data.
  16. Patient is unable or unwilling, in the opinion of the investigator, to comply with the protocol.
  17. Patient (or patient's mother, if the patient is being breastfed) has previously received durlobactam.
  18. Patient (or patient's mother, if the patient is being breastfed) has received sulbactam and/or sulbactam-containing regimens (eg, Unasyn) within 72 hours of first dose of the study drug.
  19. Patient (or patient's mother, if the patient is being breastfed) has received amphotericin B within 7 days of first dose of the study drug.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    Pediatric patients 12 years to \<18 years of age Sulbactam 25mg/kg -Durlobactam 25mg/kg, not to exceed 1g sulbactam - 1g durlobactam (Every 6 hours)

    Drug: Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours)

  • Experimental
    Cohort 2

    Pediatric patients 6 years to \<12 years of age Sulbactam 25mg/kg -Durlobactam 25mg/kg, not to exceed 1g sulbactam - 1g durlobactam (Every 6 hours)

    Drug: Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours)

  • Experimental
    Cohort 3

    Pediatric patients 1 year to \<6 years of age

    Drug: Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours)

  • Experimental
    Cohort 4

    Pediatric patients 3 months to \<1 year of age

    Drug: Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours)

  • Experimental
    Cohort 5 Subgroup 1

    Aged 2 months to \<3 months, term and preterm (gestational age \>28 weeks) Term infants will receive 25mg/kg SUL and 25mg/kg DUR Preterm infants will receive 20mg/kg SUL and 20mg/kg DUR

    Drug: Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours) · Drug: Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 8 hours)

  • Experimental
    Cohort 5 Subgroup 2

    Aged birth to \<2 months, term and preterm (gestational age \>28 weeks and post-natal age \>7 days) Term infants will receive 25mg/kg SUL and 25mg/kg DUR Preterm infants will receive 20mg/kg SUL and 20mg/kg DUR

    Drug: Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 8 hours) · Drug: Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 12 hours)

Interventions

  • DrugSulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours)

    Drug page: Sulbactam

    25mg/kg SUL and 25mg/kg DUR

    Also known as: SUL-DUR

  • DrugSulbactam 20mg/kg-Durlobactam 20mg/kg (Every 8 hours)

    Drug page: Sulbactam

    20mg/kg SUL and 20mg/kg DUR

    Also known as: SUL-DUR

  • DrugSulbactam 25mg/kg -Durlobactam 25mg/kg (Every 8 hours)

    Drug page: Sulbactam

    25mg/kg SUL and 25mg/kg DUR

    Also known as: SUL-DUR

  • DrugSulbactam 20mg/kg-Durlobactam 20mg/kg (Every 12 hours)

    Drug page: Sulbactam

    20mg/kg SUL and 20mg/kg DUR

    Also known as: SUL-DUR

06

What researchers measure

Primary outcomes

  1. Assess the pharmacokinetic (PK) parameters for maximum concentration (Cmax) of sulbactam and durlobactam

    Time frame: Day 1 and Day 3

  2. Assess the PK parameters for area under the plasma concentration-time curve from 0 to 24 hours (AUC 0-24) of sulbactam and durlobactam

    Time frame: Day 1 and Day 3

Secondary outcomes

  1. Percentage of participants experiencing Treatment Emergent Adverse Events (TEAEs)

    Defined as any adverse event occurring after exposure to the study drug or any AE that worsens in intensity or frequency

    Time frame: 28 days

  2. Percentage of TEAEs leading to study drug discontinuation

    Time frame: 28 days

  3. Incidence of related TEAEs

    Time frame: 28 days

  4. Incidence of serious TEAEs

    Time frame: 28 days

  5. Change from baseline values of liver function measured by Comprehensive Metabolic Panel (CMP)

    Time frame: Baseline and Day 28

  6. Change from baseline values of kidney function measured by CMP

    Time frame: Baseline and Day 28

  7. Change from baseline values of hemoglobin

    Time frame: Baseline and Day 28

  8. Change from baseline value of white blood cell count

    Time frame: Baseline and Day 28

  9. Change from baseline value of platelets

    Time frame: Baseline and Day 28

  10. Change from baseline value of diastolic blood pressure

    Time frame: Baseline and Day 28

  11. Change from baseline value of systolic blood pressure

    Time frame: Baseline and Day 28

  12. Change from baseline values of heart rate

    Time frame: Baseline and Day 28

  13. Change from baseline value of respiration rate

    Time frame: Baseline through Day 28

  14. Change from baseline value of temperature

    Time frame: Baseline and Day 28

07

Study locations

4 of 4 sites recruiting
  • UCLA Medical Center
    Los Angeles, California 90095, United States
    Recruiting
  • Rady Children's Hospital
    San Diego, California 92123, United States
    Recruiting
  • ECU Brody School of Medicine
    Greenville, North Carolina 27834, United States
    Recruiting
  • University of Texas Medical Branch at Galveston
    Galveston, Texas 77555-5302, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data requests may be submitted starting 6 months after primary article publication and the data will be made accessible for up to 24 months; extensions may be considered on a case-by-case basis. Access criteria: Subject to certain criteria, conditions, and exceptions and upon completion of the review

Access criteria: Subject to certain criteria, conditions, and exceptions and upon completion of the review and approval of the Research Proposal and Statistical Analysis Plan, Qualified Researchers engaging in independent scientific research can be provided de-identified IPD following the execution of a Data Sharing Agreement

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Dec 2026; primary completion for May 2028, 16 months later.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Dec 2026, on Oct 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2025
First posted
Jan 30, 2025
StartEst.
Dec 30, 2026was Oct 2026
Primary completionEst.
May 5, 2028
CompletionEst.
May 20, 2028
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 30, 2026→Dec 30, 2026
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Start date Oct 30, 2026→Dec 30, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06801223
Lead sponsor
Innoviva Specialty Therapeutics
Collaborators
Entasis Therapeutics
Responsible party
Sponsor
First posted
Jan 30, 2025
Start date
Dec 30, 2026 (estimated)
Primary completion
May 5, 2028 (estimated)
Completion
May 20, 2028 (estimated)
Last update
Oct 6, 2026

Study contacts

ISTX Clinical Trials
Contact
Clinicaltrials@istx.com
617-715-3600

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sulbactam

Start the discussion